ITGB8: A Potential Drug Target for Pain and Neurological Conditions

Target Name: ITGB8

NCBI ID: G3696

ITGB8

Other Name(s): ITB8_HUMAN | Integrin beta-8 | Integrin subunit beta 8 | integrin subunit beta 8

ITGB8: A Potential Drug Target for Pain and Neurological Conditions

ITGB8 (Integrin-like Growth Factor 8) is a protein that is expressed in various tissues throughout the body, including the nervous system, endothelial cells, and muscle fibers. Its function is not well understood, but it is known to play a role in cell-cell adhesion, migration, and survival.

ITGB8 has also been shown to be involved in the regulation of pain perception and neuroinflammation. It has been shown to interact with TrkA, a protein that is involved in pain signaling. This interaction suggests that ITGB8 may be a potential drug target for the treatment of pain.

Targeting ITGB8

One approach to targeting ITGB8 is to use small molecules that can modulate its function. One class of small molecules that have been shown to interact with ITGB8 is called inhibitors of the protein kinase CK2.

CK2 is a protein that is involved in many cellular processes, including cell signaling, cell division, and cell adhesion. It has been shown to play a role in the regulation of ITGB8 function. By inhibiting CK2, small molecules can potentially modulate the activity of ITGB8 and improve its function.

Another approach to targeting ITGB8 is to use antibodies that recognize and target specific regions of the protein. One possible approach is to use antibodies that recognize the extracellular domain (ECD) of ITGB8. The ECD is the portion of the protein that is exposed to the outside of the cell, and it is involved in many of the protein's functions.

Targeting ITGB8 with antibodies

To test the effectiveness of antibodies that recognize ITGB8, researchers have used various techniques to measure the activity of the antibodies in a cell-based assay. One approach is to use antibodies that recognize the ECD of ITGB8 and measure the ability of the antibodies to bind to the protein.

Another approach is to use antibodies that recognize ITGB8 in a cell-based assay to measure the ability of the antibodies to promote the growth or migration of ITGB8-expressing cells. This can be a useful way to measure the effectiveness of ITGB8 inhibitors.

Antibodies against ITGB8 have also been shown to be effective in animal models of disease. For example, researchers have used antibodies to block ITGB8 function in mice and to treat spinal cord injury in dogs.

Conclusion

ITGB8 is a protein that is involved in many cellular processes throughout the body. Its function is not well understood, but it is known to play a role in cell-cell adhesion, migration, and survival. ITGB8 has also been shown to be involved in the regulation of pain perception and neuroinflammation, and it has been shown to interact with the protein TrkA.

In conclusion, ITGB8 is a potential drug target for the treatment of pain and other neurological conditions. Researchers are currently working to develop small molecules and antibodies that can modulate ITGB8 function and improve its therapeutic potential. Further studies are needed to fully understand the role of ITGB8 in disease and to develop effective treatments.

Protein Name: Integrin Subunit Beta 8

Functions: Integrin alpha-V:beta-8 (ITGAV:ITGB8) is a receptor for fibronectin (PubMed:1918072). It recognizes the sequence R-G-D in its ligands (PubMed:1918072). Integrin alpha-V:beta-6 (ITGAV:ITGB6) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation on the surface of activated regulatory T-cells (Tregs) (Probable). Required during vasculogenesis (By similarity)

The "ITGB8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITGB8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets